Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
A Nigerian hematologist will pursue a PhD in health policy at the University of Tennessee Health Science Center to help advance her work on programs for sickle cell disease (SCD) in her home country.
Infections in sickle cell disease can be problematic and even fatal. Columnist Oluwatosin Adesoye, a patient and doctor, has ...